Prospective memory deficit associated with major depressive disorder: Causality, clinical impact, and potential molecular mechanisms

< 0.05). Among 134 patients with follow-up, linear mixed-effects models revealed slower HAMD reduction in patients with PM deficits (z = 2.287, P = 0.022). PM performance showed no significant change after treatment (P = 0.117). To investigate potential mechanisms and therapeutics, shared targets for MDD and PM were identified through network pharmacology and summary-data-based MR, revealing Rap1 signaling as the top enriched pathway with eight core targets. Molecular docking showed relatively weak predicted affinities (mean > -7.5 kcal/mol) of commonly used antidepressants to these targets. Virtual screening of psychiatric compounds identified Hypericin, with strong affinity to the core targets (mean -9.06 kcal/mol). In conclusion, MDD may increase the risk of PM deficits, which are associated with poorer treatment response and show limited improvement following current antidepressant treatments. Rap1-related mechanisms may be involved, and Hypericin may be considered a compound for further investigation.

Authors

Institutions

Publication Details

Journal
Neurotherapeutics
Published
2026-11-13
DOI
https://doi.org/10.1016/j.neurot.2026.e01115
Primary Topic
Treatment of Major Depression
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Prospective memory deficit associated with major depressive disorder: Causality, clinical impact, and potential molecular mechanisms

Xu Han, Qidi Diao, Yan Wang, Kun Zhang et al.
6 links
Neurotherapeutics
Treatment of Major Depression
article

Prospective memory deficit associated with major depressive disorder: Causality, clinical impact, and potential molecular mechanisms

Xu Han, Qidi Diao, Yan Wang, Kun Zhang, Yufei Ma, Junyuan Sun, Lei Hu, Weihua Yue, Kai Zhang, Yihan Ma, Jiani Li, Xinyun Yuan
article en

Abstract

< 0.05). Among 134 patients with follow-up, linear mixed-effects models revealed slower HAMD reduction in patients with PM deficits (z = 2.287, P = 0.022). PM performance showed no significant change after treatment (P = 0.117). To investigate potential mechanisms and therapeutics, shared targets for MDD and PM were identified through network pharmacology and summary-data-based MR, revealing Rap1 signaling as the top enriched pathway with eight core targets. Molecular docking showed relatively weak predicted affinities (mean > -7.5 kcal/mol) of commonly used antidepressants to these targets. Virtual screening of psychiatric compounds identified Hypericin, with strong affinity to the core targets (mean -9.06 kcal/mol). In conclusion, MDD may increase the risk of PM deficits, which are associated with poorer treatment response and show limited improvement following current antidepressant treatments. Rap1-related mechanisms may be involved, and Hypericin may be considered a compound for further investigation.

NeurotherapeuticsVol. 24(1)
Shandong University (CN), Peking University (CN), Shandong Mental Health Center (CN), Affiliated Hospital of Jining Medical University (CN), Peking University Sixth Hospital (CN), Jining Medical University (CN)
National Natural Science Foundation of China, Beijing Nova Program
Good health and well-being
Treatment of Major Depression
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon